Journal Article

DKFZ-2021-00848

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Daratumumab, lenalidomide, and dexamethasone in systemic light-chain amyloidosis: High efficacy, relevant toxicity and main adverse effect of gain 1q21

Kimmich, C. R. ; Terzer, T. ; Benner, A.DKFZ* ; Hansen, T. ; Carpinteiro, A. ; Dittrich, T. ; Veelken, K. ; Jauch, A. ; Huhn, S. ; Basset, M. ; Goldschmidt, H. ; Müller-Tidow, C. ; Schönland, S. O. ; Hegenbart, U.

2021
Wiley-Liss New York, NY

This record in other databases:  

Please use a persistent id in citations: doi:10.1002/ajh.26191

Note: 2021 Jul 1;96(7):E253-E257 /Daratumumab, lenalidomide, and dexamethasone in systemic light-chain amyloidosis: High efficacy, relevant toxicity and main adverse effect of gain 1q21

---

Contributing Institute(s):

1. C060 Biostatistik (C060)

Research Program(s):

1. 313 - Krebsrisikofaktoren und Prävention (POF4-313) (POF4-313)

Appears in the scientific report 2021

---

Database coverage:
; BIOSIS Previews ; Biological Abstracts ; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; Current Contents - Life Sciences ; DEAL Wiley ; Essential Science Indicators ; IF >= 5 ; JCR ; Nationallizenz ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection

---